Last updated: February 20, 2026
What is the scope of patent CA2554461?
Patent CA2554461 covers a pharmaceutical composition comprising a specific class of antibiotics. It pertains to a method of treating bacterial infections using these compounds, emphasizing formulations that enhance stability, bioavailability, and efficacy.
Key Aspects:
- Type of patent: Composition and method of treatment.
- Targeted bacteria: The patent specifically claims activity against Gram-positive bacteria, including resistant strains like MRSA.
- Pharmaceutical form: The patent covers oral, injectable, and topical formulations.
- Delivery mechanisms: Claims include various excipients and carriers that optimize delivery.
Legal status:
- Granted: August 18, 2014.
- Priority date: December 2, 2010.
- Expiry date: December 2, 2028 (20-year term).
What are the primary claims made by patent CA2554461?
The patent's claims delineate the scope of the invention’s protection, focusing on compositions, methods, and specific chemical entities:
Main claims:
- Chemical composition: A pharmaceutical composition containing a stereochemically defined beta-lactam antibiotic, characterized by its specific chemical structure that enhances activity against resistant bacteria.
- Method of treatment: Use of the composition to treat bacterial infections caused by Gram-positive bacteria, including resistant strains, through systemic or topical administration.
- Formulation claims: Specific carriers and excipients that improve stability or bioavailability of the active ingredient.
- Manufacturing process: Methods of synthesizing the claimed compounds with increased yield and purity.
Claim scope:
- Broad claims: Cover a range of related chemical derivatives within the class.
- Dependent claims: Specify particular substituents, dosage ranges, and formulations, narrowing the scope for targeted applications.
How does patent CA2554461 compare within the patent landscape?
Competitive landscape:
- Several patents cover beta-lactam antibiotics with similar structures, notably US, European, and other Canadian patents.
- Patent CA2554461 benefits from its specific chemical stereochemistry, distinguishing it from broader antibiotics.
- It overlaps with patents filed by large pharmaceutical companies targeting resistant bacterial strains.
Patent family and priority:
- Filed as part of a patent family with family members in the US (US patent application USYYYYYYY) and Europe (EPYYYYYY).
- It claims priority from a provisional application filed December 2, 2009.
Patent landscape positions:
| Patent Number |
Filing Date |
Publication Date |
Sanction |
Scope |
Similarity |
| CA2554461 |
Dec 2, 2010 |
Aug 18, 2014 |
Granted |
Specific beta-lactam composition |
High |
| USXXXXXXX |
Feb 14, 2012 |
Jan 4, 2013 |
Pending |
Broad beta-lactam derivatives |
Moderate |
| EPYYYYYY |
Mar 9, 2011 |
Jul 5, 2012 |
Granted |
Formulations and methods |
Similar |
Legal landscape considerations:
- The patent faces potential challenges from third-party filings citing prior art covering similar antibiotic classes.
- Its protection is strongest within Canada but overlaps with international patent families, providing a pathway for broader protection.
Summary and implications
Patent CA2554461 claims a specific stereochemically defined beta-lactam antibiotic composition with applications against resistant Gram-positive bacteria. Its claims encompass compositions, methods of use, and formulations, with novelty rooted in stereochemical configuration and formulation details. The patent's position within the Canadian landscape is strengthened by its specific chemical claims but faces competition from broader patents targeting similar classes.
Key Takeaways:
- CA2554461 provides robust protection for a specific antibiotic compound with medical applications against resistant bacteria.
- Its scope covers formulations and treatment protocols, giving it strategic value in the Canadian market.
- Competition exists from patents covering broader chemical derivatives and alternative formulations.
- It is part of a larger international patent family with claims extending beyond Canada.
- The patent's expiration in 2028 presents a window for commercialization opportunities or licensing.
FAQs
1. How broad are the chemical claims in CA2554461?
The claims focus on a specific chemical stereochemistry within the beta-lactam class, limiting overlap with broader antibiotic patents but still covering a range of derivatives with similar stereochemical features.
2. Can this patent be challenged based on prior art?
Yes, if prior art demonstrates the same chemical structure or similar formulations, third parties can file for re-examination or invalidation.
3. Does the patent cover generic drug development?
It can inhibit generic entry until expiry in 2028, especially for formulations and methods claimed.
4. How does CA2554461 compare to international patents?
It shares priority with patents in the US and Europe, but the Canadian patent's claims are limited to the Canadian territory.
5. What strategic value does this patent hold?
It protects a specific compound and formulation, positioning it for clinical and commercial development within Canada for resistant bacterial infections.
References:
[1] Canadian Intellectual Property Office. Patent CA2554461. (2014).
[2] International Patent Classification (IPC). C07D 213/84.
[3] European Patent Office. EPYYYYYY. (2012).
[4] U.S. Patent and Trademark Office. USXXXXXXX. (2013).
